| Literature DB >> 33297955 |
Nan Gao1, Xiaoyong Qi2, Yi Dang3, Yingxiao Li3, Gang Wang4, Xiao Liu3, Ning Zhu1, Jinguo Fu4.
Abstract
BACKGROUND: Currently, how to accurately determine the patient prognosis after a percutaneous coronary intervention (PCI) remains unclear and may vary among populations, hospitals, and datasets. The aim of this study was to establish a prediction model of in-hospital mortality risk after primary PCI in patients with acute ST-elevated myocardial infarction (STEMI).Entities:
Keywords: Hospital mortality; Nomogram; Percutaneous coronary intervention; Predictive value of tests; ST-elevated myocardial infarction
Year: 2020 PMID: 33297955 PMCID: PMC7727168 DOI: 10.1186/s12872-020-01804-7
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Clinical characteristics of the patients in the training and validation sets used to construct the nomogram, according to the in-hospital mortality status
| Clinical characteristics | Training set (n = 1169) | Validation set (n = 316) | ||||
|---|---|---|---|---|---|---|
| In-hospital mortality (n = 95) | Survival (n = 1074) | In-hospital mortality (n = 25) | Survival (n = 291) | |||
| Male | 60 (63.2) | 816 (76.0) | 0.006* | 18 (72.0) | 207 (71.1) | 0.927 |
| Age (years) | 66.3 ± 13.3 | 59.6 ± 11.4 | < 0.001* | 66.0 ± 14.2 | 60.0 ± 12.1 | 0.298 |
| BMI (kg/m2) | 25.0 ± 3.9 | 25.5 ± 3.3 | 0.011* | 25.5 ± 4.0 | 25.4 ± 3.4 | 0.077 |
| Drinking history | 22 (23.2) | 297 (27.7) | 0.346 | 8 (32.0) | 68 (23.4) | 0.332 |
| Smoking history | 35 (36.8) | 518 (48.2) | 0.033* | 8 (32.0) | 121 (41.6) | 0.350 |
| DM history | 26 (27.4) | 214 (19.9) | 0.085 | 7 (28.0) | 59 (20.3) | 0.362 |
| Hypertension history | 51 (53.7) | 516 (48.0) | 0.292 | 10 (40.0) | 139 (47.8) | 0.455 |
| Killip classification | < 0.001* | < 0.001* | ||||
| I | 35 (36.8) | 939 (87.4) | 12 (48.0) | 262 (90.0) | ||
| II | 14 (14.7) | 110 (10.2) | 5 (20.0) | 21 (7.2) | ||
| III | 8 (8.4) | 18 (1.7) | 1 (4.0) | 6 (2.1) | ||
| IV | 38 (40.0) | 7 (0.7) | 7 (28.0) | 2 (0.7) | ||
| LMCAD | 7 (7.4) | 3 (0.3) | < 0.001* | 2 (8.0) | 1 (0.3) | < 0.001* |
| Grading of thrombus | 0.005* | 0.340 | ||||
| 0 | 0 | 6 (0.6) | 0 | 2 (0.7) | ||
| 1 | 0 | 15 (1.4) | 3 (12.0) | 5 (1.7) | ||
| 2 | 2 (2.1) | 96 (8.9) | 3 (12.0) | 32 (11.0) | ||
| 3 | 29 (30.5) | 450 (41.9) | 6 (24.0) | 131 (45.0) | ||
| 4 | 44 (46.3) | 348 (32.4) | 10 (40.0) | 94 (32.3) | ||
| 5 | 20 (21.1) | 159 (14.8) | 3 (12.0) | 42 (14.4) | ||
| TIMI classification | < 0.001* | < 0.001* | ||||
| 0 | 16 (16.8) | 1 (0.1) | 6 (24.0) | 0 | ||
| 1 | 10 (10.2) | 2 (0.2) | 3 (12.0) | 1 (0.3) | ||
| 2 | 12 (12.6) | 57 (5.3) | 2 (8.0) | 15 (5.1) | ||
| 3 | 57 (60.0) | 1014 (94.4) | 14 (56.0) | 275 (94.5) | ||
| Slow flow | 41 (43.2) | 86 (8.0) | < 0.001* | 7 (28.0) | 25 (8.6) | < 0.001* |
| Application of IABP | 18 (19.0) | 14 (1.3) | < 0.001* | 4 (16.0) | 3 (1.0) | < 0.001* |
| Administration of β-blocker | 32 (33.7) | 809 (75.3) | < 0.001* | 6 (24.0) | 236 (81.1) | < 0.001* |
| ACEI/ARB | 20 (21.1) | 644 (60.0) | < 0.001* | 5 (20.0) | 186 (63.9) | 0.003* |
| Symptom-to-door time (min) | 256 ± 235 | 89 ± 73 | < 0.001* | 248 ± 226 | 85 ± 74 | < 0.001* |
| Symptom-to-balloon time (min) | 426 ± 244 | 236 ± 153 | < 0.001* | 420 ± 269 | 234 ± 157 | < 0.001* |
| Syntax score | 29.3 ± 9.9 | 20.7 ± 7.7 | 0.003* | 31.9 ± 13.1 | 20.9 ± 7.9 | 0.003* |
| EF (%) | 47.2 ± 8.5 | 54.6 ± 8.1 | 0.918 | 45.1 ± 7.4 | 54.7 ± 7.64 | 0.926 |
| CK-MB (U/L) | 180.0 ± 157.2 | 156.4 ± 58.2 | < 0.001* | 175.3 ± 197.5 | 158.9 ± 54.7 | 0.019* |
| Random blood glucose (mmol/L) | 9.25 ± 3.51 | 8.06 ± 2.83 | 0.056 | 9.3 (7.4,15.71) | 7.1 (6.19,9.28) | 0.001* |
| Triglycerides (mmol/L) | 1.42 (1.01,1.80) | 1.43 (0.99,1.99) | 0.687 | 1.28 (0.98,1.71) | 1.49 (0.99,1.99) | 0.290 |
*P < 0.05 between the in-hospital mortality and survival groups
BMI body mass index, DM diabetes mellitus, LMCAD left main coronary artery disease, TIMI thrombolysis in myocardial infarction, IABP intra-aortic balloon pump, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, EF ejection fraction, CK-MB creatinine kinase MB
Fig. 1Texture feature selection using the least absolute shrinkage and selection operator (LASSO) binary logistic regression model. a The tuning parameter (λ) selection in the LASSO model used tenfold cross-validation via minimum criteria. The area under the receiver operating characteristic (AUC) curve was plotted versus log(λ). Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 standard error of the minimum criteria. The λ value was 0.003. b LASSO coefficient profiles of the 81 features. A coefficient profile plot was produced against the log(λ) sequence. Vertical lines were drawn at the value selected using tenfold cross-validation, where optimal λ resulted in 14 non-zero coefficients
Fig. 2The mortality risk prediction nomogram. SDT: symptom-to-door time; SBT: symptom-to-balloon time; LMCAD: left main coronary artery disease; TIMI: thrombolysis in myocardial infarction; IABP: intra-aortic balloon pump; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; EF: ejection fraction; CK-MB: creatinine kinase MB; B: β-blocker
Fig. 3a Validation of the prediction model in the training set b validation of the prediction model in the validation set
Fig. 4a Receiver operating characteristic (ROC) curve of the nomogram in the training set (area under the curve (AUC) = 0.987, 95% confidence interval (CI): 0.981–0.994, P = 0.003). Sensitivity was 97.9%, specificity was 91.6%. b ROC curve of the nomogram in the validation set (AUC = 0.990, 95% CI: 0.987–0.998, P = 0.007). Sensitivity was 94.7%, specificity was 95.1%
Fig. 5Decision curve analysis (DCA) shows that the nomogram can achieve good net benefit
Analysis based on diabetes
| Death (n = 95) | Survival (n = 1074) | ||
|---|---|---|---|
| Random blood glucose (mmol/L) | |||
| ≤ 10 | 67 (70.5%) | 836 (77.8%) | 0.103 |
| > 10 | 28 (29.5%) | 238 (22.2%) | |
| Treatments | |||
| Diet management | 2 (8.7%) | 14 (6.5%) | 0.813 |
| Oral hypoglycemic drugs | 14 (60.9%) | 124 (57.1%) | |
| Insulin with or without oral hypoglycemic drugs | 7 (30.4%) | 79 (36.4%) | |